+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics: Distribution by Type of Protein degrader, Therapeutic Areas, Route of administration, Key Contributing Technologies and Key Geographies, 2021-2030

  • ID: 5359100
  • Report
  • March 2021
  • Region: Global
  • 330 Pages
  • Roots Analysis

FEATURED COMPANIES

  • 6 Dimensions Capital
  • Casdin Capital
  • Fjärde AP-fonden
  • Kymera Therapeutics
  • Oxford Finance
  • SR One

Overview

Targeted protein degradation is a revolutionary pharmacological concept that presents viable drug development opportunities and is anticipated to introduce a new paradigm in modern therapeutic interventions. Due to various reasons, conventional drugs / therapies have been limited in terms of their capability to target certain proteins of pathological significance. Presently, medical researchers engaged in the development of bifunctional protein degrader-based interventions claim that this upcoming class of drugs is capable of targeting biomolecules in the human proteome, which were previously considered undruggable. The concept of targeted protein degradation revolves around the use of small molecule leads, which are capable of recruiting the ubiquitin-proteasome system (UPS) to selectively eliminate a target biomolecule. In other words, protein degraders regulate biological pathways by selectively downregulating a target protein by degrading them; this process has been shown to be robust, more sensitive to drug-resistant targets and can regulate cellular functions that are not dependent on enzyme action. Moreover, drugs designed based on this relatively novel concept, have been shown to demonstrate a remarkable level of selectivity, high potency, oral bioavailability and differentiated pharmacology, compared to traditional enzyme inhibitors. As a result, this upcoming class of drugs has garnered significant interest within the medical science community. In fact, the growing popularity of targeted protein degradation is evident in the USD 5 billion in capital investments made into companies engaged in this field of research, since 2014.

Proteolysis targeting chimera (PROTAC), developed by Hashimoto Laboratory in 2008, was the first targeted protein degrader. The incessant efforts of researchers involved in this domain have resulted in significant progress towards understanding the physiochemical and biological properties of such bifunctional molecules. Presently, there are several other types of targeted protein degraders and molecular glues, which have been / are being developed for the treatment of a variety of clinical conditions, including acute myeloid leukemia, Alzheimer's disease, breast cancer, myelofibrosis, multiple myeloma, Parkinson's disease, prostate cancer, psoriasis, rheumatoid arthritis, and supranuclear palsy. It is worth noting that the R&D efforts in this field are supported by DNA-encoded libraries and other in silico hit discovery and characterization tools. In the last 4-5 years, there has been a marked rise in the number of new entrants in this market. Additionally, several big pharma players are also actively involved in this field, evaluating proprietary protein degrader-based therapeutic leads. The market has also witnessed substantial partnership activity over the last few years, with several technology developers involved in high-value licensing deals. Although, there are no approved protein degrader-based drugs / therapy products, the market is poised to witness healthy growth over the next decade.

Scope of the Report

The ‘Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics (2nd Edition), 2021-2030: Distribution by Type of Protein degrader (degronimids, PROTACs, SARDs / SERDs, and specific BET and DUB inhibitors, and other inhibitors), Therapeutic Area (Neurological Disorders, Oncological Disorders, and Other Therapeutic Areas), Route of administration (Oral, Intravenous and Others), Key Contributing Technologies and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World)’ report features an extensive study of the current and future potential of protein degraders, offering an informed opinion on the likely adoption of these therapeutics and affiliated technologies, over the next decade. The focus of this study is on specially designed small molecule degraders, including degronimids, endosome targeting chimeras (ENDTACs), epichaperome inhibitors, hydrophobic tags, immuno-modulatory imide drugs (IMiDs), lysosome targeting chimeras (LYTACs), molecular glues, photochemically targeting chimeras (PHOTACs), proteolysis targeting chimeras (PROTACs), protein homeostatic modulators, selective androgen receptor degraders (SARDs), selective estrogen receptor degraders (SERDs), specific and non-genetic IAP-dependent protein erasers (SNIPERs), and specific bromodomain and extra-terminal motif (BET) inhibitors and deubiquitinase (DUB) inhibitors. In addition, the report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.  

Amongst other elements, the report includes:

  • A detailed review of the current market landscape of targeted protein degradation-based therapeutics, including information on type of protein degrader (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phase of development (clinical, preclinical, and discovery stage) of product candidates, target indication(s), key therapeutic area(s), type of biological target(s), associated ubiquitin ligase(s) (if available), target signaling pathway (if available), mechanism of action (if available), type of therapy (monotherapy and combination therapy), route of administration (oral, intravenous and others). In addition, it presents a list on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), clinical study sponsor(s) and collaborator(s). 
  • An overview of the overall landscape of target protein degradation enabling technologies, featuring an analysis based on type of degrader. In addition, it presents a list of targeted protein degradation enabling technology developers and analysis based on various parameters, such as year of establishment, company size and location of headquarters. 
  • Detailed profiles of prominent players engaged in the development of targeted protein degraders (shortlisted on the basis of phase of development of pipeline products). Each profile features a brief overview of the company, its financial information (if available), detailed description of their respective lead drug candidates, and recent developments and an informed future outlook. Additionally, each drug profile features information on the type of drug, current status of development, route of administration, target indications, and a brief summary of its developmental history. 
  • Tabulated profiles of leading industry players (shortlisted on the basis of the number of candidates in development pipeline). Each profile includes details on the innovator company (such as year of establishment, location of headquarters, number of employees, and key members of the executive team), recent developments, along with information on respective drug candidates. 
  • An in-depth analysis of completed, ongoing and planned studies of various targeted protein degraders, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of protein degrader, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), trial focus, target therapeutic area, key indications, and clinical endpoints.
  • A detailed analysis of grants that have been awarded to various research institutes for targeted protein degradation projects, in the period between 2017 and 2020, on the basis of important parameters, such as year of award, amount awarded, administering institute center, support period, funding mechanism, type of grant application, purpose of grant award, activity code, emerging focus areas of the grants, study section, popular NIH departments, study section, and type of recipient organization, highlighting popular recipient organizations, popular program officers and regional distribution of recipient organizations.  
  • A detailed publication analysis peer-reviewed, scientific articles that have been published between 2017 and Q3 2019, highlighting the research focus within the industry. It also highlights the key trends observed across publications, including information on type of publication, year of publication, study objective, popular keywords, type of protein degrader, biological target, associated ubiquitin enzyme, number of publications, type of publisher, leading players (in terms of number of publications), region, and key journals (in terms of number of articles published in this domain and impact factor of the journal). 
  • An insightful analysis of the patents filed / granted for targeted protein degradation enabling technologies, since 2018, taking into consideration various parameters, such as type of patent, publication year, geographical location, type of applicant, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. The chapter also includes a detailed patent benchmarking and an insightful valuation analysis.
  • A list of key opinion leaders (KOLs) within this domain, and their assessment (based on the strength and activeness) represented in the form of 2×2 matrices. The chapter also includes a schematic world map representation (highlighting the geographical locations of eminent scientists / researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).
  • An analysis of the partnerships that have been established in this domain, during the period 2014-2020, covering research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals.
  • An analysis of the investments in the form of seed financing, venture capital financing, debt financing, grants / awards, initial public offerings (IPOs) and subsequent offerings, made at various stages of development of the companies engaged in this field.
  • A detailed deal structure analysis, highlighting cash flows and net present values of licensor and licensee, taking into consideration multiple likely scenarios of upfront, milestone and royalty payments.

One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities of novel technologies for the development of targeted protein degraders. Based on the likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided informed estimates on the evolution of the market over the period 2021-2030. For estimating the future market opportunities for technology providers, we have considered the likely licensing deal structures and agreements that are likely to be established in the foreseen future. The future opportunity within the targeted protein degradation market has been segmented across [A] different types of protein degraders (degronimids, PROTACs, SARDs / SERDs, Specific BET and DUB Inhibitors, and other inhibitors), [B] therapeutic areas (oncological disorders, neurological disorders, and other therapeutic areas), [C] route of administration (oral route, intravenous route, and other routes), and [D] key geographical regions (North America, Europe and Asia Pacific). In order to account for future uncertainties associated with the growth of targeted protein degradation market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. 

The report features detailed transcripts of interviews held with the following individuals (in alphabetical order):

  • Laura Itzhaki, Founder and Chief Scientific Officer, Polyprox Therapeutics
  • Louise Bergeron, Vice President, Xios Therapeutics
  • Martin Wiles, Vice President Business Development and Licensing, Almac Discovery & Gerald Gavory, Director of Biology, Almac Discovery
  • Jason Brown, Scientific and Business Development Director, Ubiquigent
  • Anonymous, Director of Oncology Research, Large Company
  • Anonymous, Chief Scientific Officer, Very Small Company
  • Paul Wallace, Chief Business Officer, Mission Therapeutics
  • Katrin Rittinger, Research Group Leader, Francis Crick Institute
  • Zhihao Zhuang, Associate Professor, Department of Chemistry and Biochemistry, University of Delaware

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading industry and non-industry players engaged in this market?
  • What are the key therapeutic areas for which target protein degraders are being / have been developed?
  • Which geographies are the most active in conducting clinical trials on target protein degraders?
  • What kind of partnership models are commonly adopted by industry stakeholders? 
  • Which are the leading administering institute centers supporting the research related to this domain?
  • What is the trend of capital investments in the targeted protein degradation market?
  • How has the intellectual property landscape in this market evolved over the years?
  • How is the current and future market opportunity likely to be distributed across key market segments
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 6 Dimensions Capital
  • Casdin Capital
  • Fjärde AP-fonden
  • Kymera Therapeutics
  • Oxford Finance
  • SR One

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Context and Background
3.2. Protein Homeostasis
3.3. Post Translational Protein Modifications
3.4. Ubiquitin and the Ubiquitin Proteasome System (UPS)
3.4.1. Structure and Functions of Ubiquitin
3.4.2. Overview of the UPS
3.4.2.1. Components of the UPS
3.4.2.2. Ubiquitin-based Protein Degradation Pathway
3.5. Therapeutic Applications of the UPS
3.6. Ubiquitin Enzyme Inhibitors
3.6.1. Advantages and Challenges
3.7. Overview of Targeted Protein Degradation
3.7.1. Historical Development of Protein Degraders
3.7.2. Types of Protein Degraders
3.7.2.1. Proteolysis Targeting Chimeras (PROTACs)
3.7.2.2. Other Chimeric Protein Targeting Molecules
3.7.2.2.1. Endosome Targeting Chimeras (ENDTACs)
3.7.2.2.2. Lysosome Targeting Chimeras (LYTACs)
3.7.2.2.3. Photochemically Targeted Chimeras (PHOTACs)
3.7.2.3. Epichaperome Inhibitors
3.7.2.4. Hydrophobic Tags
3.7.2.5. Immuno-modulatory Imide Drugs (IMiDs)
3.7.2.6. Molecular Glues
3.7.2.7. Protein Homeostatic Modulators
3.7.2.8. Selective Hormone Receptor Degraders (SHRDs)
3.7.2.9. Specific and Non-genetic IAP-dependent Protein Erasers (SNIPERs)
3.7.2.10. Specific Bromodomain and Extra-terminal Motif (BET) Inhibitors and Deubiquitinase (DUB) Inhibitors
3.8. Market Growth Drivers and Roadblocks
3.9. Recent Developments and Upcoming Trends

4. CURRENT MARKET LANDSCAPE: TARGET PROTEIN DEGRADATION-BASED THERAPEUTICS
4.1. Chapter Overview
4.2. Targeted Protein Degradation-based Therapeutics: Development Pipeline
4.2.1. Analysis by Type of Protein Degrader
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Target Indication
4.2.5. Analysis by Biological Target
4.2.6. Analysis by Associated Ubiquitin Ligase
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Route of Administration
4.3. Targeted Protein Degradation-based Therapeutics: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Type of Protein Degrader
4.3.4. Analysis by Location of Headquarters
4.3.5. Leading Players: Analysis by Number of Drug Candidates

5. CURRENT MARKET LANDSCAPE: TARGET PROTEIN DEGRADATION ENABLING TECHNOLOGIES
5.1. Chapter Overview
5.2. Targeted Protein Degradation Enabling Technologies: List of Research Tools / Key Technology Platforms
5.2.1. Analysis by Type of Protein Degrader
5.2.2. Analysis by Number of Drugs under Development
5.3. Targeted Protein Degradation Enabling Technologies: Developer Landscape
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Developers with Late-stage Clinical Candidates
6.2.1. Radius Health
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Targeted Protein Degradation-based Product Portfolio
6.2.1.3.1. Elacestrant (RAD1901)
6.2.1.4. Recent Developments and Future Outlook
6.2.2. Celgene
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Targeted Protein Degradation-based Drug Portfolio
6.2.2.3.1. Avadomide (CC-122)
6.2.2.3.2. Iberdomide (CC-220)
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Sanofi Genzyme
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Targeted Protein Degradation-based Drug Portfolio
6.2.3.3.1. SAR439869
6.2.3.4. Recent Developments and Future Outlook
6.2.4. AstraZeneca
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Targeted Protein Degradation-based Drug Portfolio
6.2.4.3.1. AZD9833
6.2.4.4. Recent Developments and Future Outlook
6.3. Developers with Preclinical / Early-stage Clinical Candidates
6.3.1. Arvinas
6.3.2. BioTheryX
6.3.3. Captor Therapeutics
6.3.4. C4 Therapeutics
6.3.5. Genentech
6.3.6. Hinova Pharmaceuticals
6.3.7. Kangpu Biopharmaceuticals
6.3.8. Kymera Therapeutics
6.3.9. Mission Therapeutics
6.3.10. Progenra
6.3.11. Zenopharm

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Clinical Trials
7.3.1. Analysis by Trial Registration Year
7.3.2. Geographical Analysis by Number of Clinical Trials
7.3.3. Geographical Analysis by Enrolled Patient Population
7.3.4. Analysis by Type of Protein Degrader
7.3.5. Analysis by Trial Phase
7.3.6. Analysis by Study Design
7.3.7. Analysis by Type of Sponsor / Collaborator
7.3.8. Most Active Players: Analysis by Number of Registered Trials
7.3.9. Analysis by Trial Focus
7.3.10. Analysis by Therapeutic Area
7.3.11. Analysis by Clinical Endpoints

8. ACADEMIC GRANTS ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Target Protein Degradation: Analysis of Academic Grants
8.3.1. Analysis by Year of Grant Award
8.3.2. Analysis by Amount Awarded
8.3.3. Analysis by Funding Institute Center
8.3.4. Analysis by Support Period
8.3.5. Analysis by Funding Institute Center and Support Period
8.3.6. Analysis by Type of Grant Application
8.3.7. Analysis by Purpose of Grant Award
8.3.8. Analysis by Activity Code
8.3.9. Emerging Focus Areas (Word Cloud)
8.3.10. Analysis by Study Section Involved
8.3.11. Popular NIH Departments: Analysis by Number of Grants
8.3.12. Analysis by Type of Recipient Organization
8.3.13. Prominent Program Officers: Analysis by Number of Grants
8.3.14. Popular Recipient Organizations: Analysis by Number of Grants
8.3.15. Regional Distribution of Recipient Organizations

9. PUBLICATION ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Targeted Protein Degradation-Based Therapeutics and Technologies: Recent Publications
9.3.1. Analysis by Year of Publication
9.3.2. Analysis by Study Objective
9.3.3. Emerging Focus Areas
9.3.4. Analysis by Type of Protein Degrader
9.3.5. Analysis by Target Protein
9.3.6. Analysis by Target Enzyme
9.3.7. Analysis by Target Indication
9.3.8. Analysis by Type of Publisher
9.3.9. Leading Players: Analysis by Number of Publications
9.3.10. Leading Players: Geographical Analysis by Number of Publications
9.3.11. Key Journals: Analysis by Number of Publications

10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Targeted Protein Degradation Technologies: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Application Year
10.3.3. Analysis by Geographical Location
10.3.4. Analysis by CPC Symbols
10.3.5. Emerging Focus Areas (Word Cloud)
10.3.6. Analysis by Type of Organization
10.3.7. Leading Players: Analysis by Number of Patents
10.4. Target Protein Degradation Technologies: Benchmarking Patent Analysis
10.4.1. Analysis by Patent Characteristics
10.5. Target Protein Degradation-based Technologies: Patent Valuation Analysis
10.6. Leading Patents by Number of Citations

11. KOL ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Principal Investigators
11.3.1. Analysis by Designation
11.3.2. Analysis by Phase of Development and Type of Protein Degrader
11.3.3. Analysis by Therapeutic Area
11.3.4. Analysis by Type of Organization
11.3.5. Analysis by Location of Organization
11.3.6. Leading Organizations: Analysis by Number of Affiliated Principal Investigators
11.4. Prominent Key Opinion Leaders (KOLs)
11.5. KOL Benchmarking: Publisher versus Third Party Scoring (ResearchGate Score)
11.6. Profiles of Most Active KOLs
11.6.1. Profile: KOL A (Barbara Ann Karmanos Cancer Center)
11.6.2. Profile: KOL B (Celgene)
11.6.3. Profile: KOL C (Feinberg School of Medicine, Northwestern University)
11.6.4. Profile: KOL D (Royal Marsden NHS Foundation Trust)
11.6.5. Profile: KOL E (Samus Therapeutics)
11.6.6. Profile: KOL F (Stanford Women Cancer Center)
11.6.7. Profile: KOL G (University of North Carolina at Chapel Hill)
11.6.8. Profile: KOL H (University of Toledo)

12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. Targeted Protein Degradation-based Therapeutics and Technologies: Recent Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Type of Protein Degrader
12.3.4. Analysis by Protein Degradation Technology
12.3.5. Analysis by Therapeutic Area
12.3.6. Most Active Players: Analysis by Number of Partnerships
12.3.7. Geographical Analysis
12.3.7.1. Most Active Players: Regional Analysis by Number of Partnerships
12.3.7.2. Intercontinental and Intracontinental Agreements

13. FUNDING AND INVESTMENT ANALYSIS
13.1. Chapter Overview
13.2. Types of Funding
13.3. Targeted Protein Degradation-based Therapeutics and Technologies: Recent Funding Instances
13.3.1. Analysis by Year of Investment
13.3.2. Analysis by Amount Invested
13.3.3. Analysis by Type of Funding
13.3.4. Analysis by Amount Invested for Different Types of Degraders
13.3.5. Analysis by Amount Invested across Different Therapeutic Areas
13.3.6. Analysis by Amount Invested across Different Technology Platforms
13.3.7. Most Active Players: Analysis by Number of Funding Instances and Amount Invested
13.3.8. Most Active Investors: Analysis by Participation
13.3.9. Geographical Analysis by Amount Invested
13.4. Concluding Remarks

14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Assumptions and Methodology
14.3. Targeted Protein Degradation-based Therapeutics and Technologies: Information on Licensing Deals
14.4. Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, 2021-2030
14.4.1. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader
14.4.1.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, 2021-2030
14.4.1.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, 2021-2030
14.4.1.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs / SERDs, 2021-2030
14.4.1.4. Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, 2021-2030
14.4.1.5. Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Inhibitors, 2021-2030
14.4.2. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area
14.4.2.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, 2021-2030
14.4.2.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurological Disorders, 2021-2030
14.4.2.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, 2021-2030
14.4.3. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration
14.4.3.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, 2021-2030
14.4.3.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, 2021-2030
14.4.3.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes of Administration, 2021-2030
14.4.4. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Geography
14.4.4.1. Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, 2021-2030
14.4.4.2. Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, 2021-2030
14.4.4.3. Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, 2021-2030
14.4.5. Targeted Protein Degradation-based Therapeutics and Technologies Market: Share of Key Contributing Technologies, 2021-2030

15. LICENSING DEAL STRUCTURE

16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Polyprox Therapeutics
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Laura Itzhaki, Founder and Chief Scientific Officer
16.3. Xios Therapeutics
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Louise Bergeron, Vice President
16.4. Almac
16.4.1. Company Snapshot
16.4.2. Interview Transcript: Martin Wiles, Vice President Business Development and Licensing & Gerald Gavory, Director of Biology
16.5. Ubiquigent
16.5.1. Company Snapshot
16.5.2. Interview Transcript: Jason Brown, Scientific and Business Development Director
16.6. Interview Transcript: Anonymous, Director of Oncology Research
16.7. Interview Transcript: Anonymous, Chief Scientific Officer
16.8. Mission Therapeutics
16.8.1. Company Snapshot
16.8.2. Paul Wallace, Chief Business Officer
16.9. Francis Crick Institute
16.9.1. Company Snapshot
16.9.2. Interview Transcript: Katrin Rittinger, Research Group Leader
16.10. University of Delaware
16.10.1. Company Snapshot
16.10.2. Interview Transcript: Zhihao Zhuang, Associate Professor, Department of Chemistry and Biochemistry

17. CONCLUDING REMARKS

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Note: Product cover images may vary from those shown
  • 6 Dimensions Capital
  • AbbVie
  • Abingworth
  • Advantech Capital
  • Advent Life Sciences
  • AIHC Capital
  • Aisling Capital
  • AJU IB Investment
  • Alexandria Venture Investments
  • Alfred Berg
  • Almac Discovery
  • Alpha Stem Cell Clinic
  • Altitude Life Science Ventures
  • AM Capital
  • Amgen
  • Amgen Ventures
  • Amphista Therapeutics
  • Amzak Health
  • ARCH Venture Partners
  • Arpeggio Biosciences
  • Arvinas
  • AstraZeneca
  • Atlas Venture
  • Avista Pharma Solutions
  • Bain Capital Life Sciences
  • Bayer
  • Beactica
  • BeiGene
  • Bellco Capital
  • Bessemer Venture Partners
  • Beth Israel Deaconess Medical Center
  • BeyondSpring Pharmaceuticals
  • Biogen
  • BioMotiv
  • BioRap Technologies
  • Biotech Investment Fund
  • BioTheryX
  • BlackRock
  • Boehringer Ingelheim
  • Borun Investment
  • Brigham And Women's Hospital
  • Bristol Myers Squibb
  • BVF Partners
  • C4 Therapeutics
  • Calico
  • California Institute for Regenerative Medicine
  • Cambridge Enterprise
  • Cambridge Innovation Capital
  • Cambridge Stem Cell Institute
  • Cancer Prevention & Research Institute of Texas
  • Cancer Research Technology
  • Cancer Research UK Manchester Institute
  • Capital Pathology Bega
  • Captor Therapeutics
  • Cardinal Partners
  • Carmot Therapeutics
  • Casdin Capital
  • CCB Medical Devices
  • Cedilla Therapeutics
  • Celgene
  • CellCentric
  • Centre for Clinical Hematology, Queen Elizabeth Hospital
  • Chengdu Dingjian
  • Children's Hospital of Philadelphia, University of Pennsylvania
  • China Construction Bank
  • Chugai Pharmaceuticals
  • ClinAssess
  • CMB International Capital
  • Cobro Ventures
  • Cormorant Asset Management
  • Cosmo Bio
  • Covance
  • Cowen
  • Cowen Private Investments
  • Crede Capital Group
  • Cullgen
  • CVC Capital Partners
  • Cyclofluidic
  • Dana-Farber Cancer Institute
  • DCVC
  • Deerfield Management
  • Dialectic Therapeutics
  • DMS Group
  • Dorian Therapeutics
  • DROIA Ventures
  • Duke University
  • Dyee Capital
  • E Fund Management
  • EcoR1 Capital
  • EG Capital
  • Eisai
  • Elan Science One
  • Eli Lilly
  • Emeriti Bio
  • EMN Research Italy
  • Eriksam Invest Aktiebolag
  • Eshelman Ventures
  • Eternal Thrive
  • European Investment Fund
  • European Myeloma Network
  • European Regional Development Fund
  • Eventide Asset Management
  • Evotec
  • Farallon Capital Management
  • Fidelity Biosciences
  • FIMECS
  • Five Elements Bio-technology
  • Fjärde AP-fonden
  • Foresite Capital
  • FORMA Therapeutics
  • Fosun
  • Franklin Templeton Investments
  • Fred Hutchinson Cancer Research Center
  • Frontier Medicines
  • G1 Therapeutics
  • Genentech
  • GF Xinde Investment Management
  • Gilead Sciences
  • GL Ventures
  • Gladiator
  • GlaxoSmithKline
  • GMIHO Medizinische Innovation -Hämatologie und Onkologie
  • GNI Group
  • GV
  • GVK Biosciences
  • H. Lee Moffitt Cancer Center and Research Institute
  • Haisco Pharmaceutical
  • Handelsbanken Fonder
  • Harvard Medical School
  • Hatteras Venture Partners
  • HBM Healthcare Investments
  • Healt Data Specialists
  • HealthCap
  • HealthCare Ventures
  • Hermed Alpha
  • HighLight Capital
  • Hinova Pharmaceuticals
  • HitGen
  • Honghui Capital
  • Horizon Discovery
  • Horizons Venture
  • Huarong Rongde Asset Management
  • Hybrigenics Pharma
  • IGM Biosciences
  • ImmunoLogik
  • Imperial Innovations
  • INIM Pharma
  • Innovate UK
  • Institute of Cancer And Genomic Science
  • Institute of Immunology and Experimental Therapy, Polish Academy of Sciences
  • InventisBio
  • Invus
  • IP Group
  • Janchor Partners
  • Janpix
  • Janssen Research & Development
  • Janus Henderson Investors
  • Jiangsu HengRui Medicine
  • Kai Kuang Pharmaceutical
  • Kangpu Biopharmaceuticals
  • Kronos Bio
  • Kymera Therapeutics
  • Kyoto University Innovation Capital
  • Lang Sheng Investment Group
  • Legend Biotech
  • Lenovo Star
  • LifeArc
  • Lilly Asia Ventures
  • Lilly Ventures
  • Longwood Fund
  • Loxo Oncology
  • Lumira Capital
  • Lycia Therapeutics
  • M Ventures
  • M.D. Anderson Cancer Center
  • Macroceutics
  • Massachusetts General Hospital
  • Matrix Capital
  • Matrix Partner China
  • McGill University
  • MD Anderson Cancer Center
  • MedImmune Ventures
  • Medivir
  • Memorial Sloan Kettering Cancer Center
  • Menarini Group
  • Merck
  • Mirae Asset Capital
  • Mission Therapeutics
  • Monte Rosa Therapeutics
  • Moonstone Investments
  • Morningside Venture Investments
  • Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute
  • Mountain Group Partners
  • MPM Capital
  • MRL Ventures Fund
  • Mubadala Ventures
  • Nanjing General Hospital of People's Liberation Army
  • Nanologica
  • National Cancer Institute
  • National Centre for Research and Development
  • National Institute of Genetics
  • National Institute of Health
  • Neotribe Ventures
  • New Enterprise Associates
  • Nextech Invest
  • Nordic Cross
  • Novartis
  • Novartis Institutes for BioMedical Research
  • Novartis Venture Fund
  • Nuevolution
  • Nurix Therapeutics
  • Nyenburgh Investment Partners
  • Oerth Bio
  • Ohio State University
  • Omega Funds
  • Oncternal Therapeutics
  • OrbiMed
  • Oriental Securities Capital
  • Orionis Biosciences
  • Oxford Finance
  • Parexel
  • Penn Medicine Abramson Cancer Center
  • Perceptive Advisors
  • Pfizer
  • Pfizer Ventures
  • Pin Therapeutics
  • Plexium
  • Polaris Partners
  • PolyProx Therapeutics
  • Profacgen
  • Progenra
  • Promega
  • Prostate Cancer Foundation
  • Proteostasis Therapeutics
  • Providence Investment
  • Proxygen
  • Pudong Innotek
  • Qiming Venture Partners
  • Queen's University
  • Quotient Sciences
  • RA Capital
  • Radius Health
  • Redmile Group
  • Roche
  • Roche Venture Fund
  • Rock Springs Capital
  • Rockefeller University
  • Roivant Sciences
  • Roswell Park Cancer Institute
  • RT Capital
  • Samus Therapeutics
  • Sanofi Genzyme
  • Sanofi Ventures
  • Schroder Adveq
  • Scottish Investment Bank
  • Seed Therapeutics
  • Sequoia Capital China
  • Seragon Pharmaceuticals
  • Servier
  • Shanghai Free Trade Zoon Equity Fund
  • Shanghai Furong Investment
  • Shenzhen Guozhong Venture Capital
  • Shenzhen Investment Holdings
  • Shenzhen Sangel Zhichuang Investment
  • SinoPharm Capital
  • Sitryx Therapeutics
  • SK Holdings
  • Sofinnova Partners
  • Solar Capital
  • Songhe Capital
  • Sosei Heptares
  • SR One
  • St. Antonius Hospital
  • Stanford University
  • Sun Pharma Advanced Research Company
  • Surveyor Capital
  • Suzhou Pioneer Pharmaceutical
  • SV Health Investors
  • SV Torch
  • Swedbank Robur
  • Sygnature Discovery
  • Takeda Pharmaceutical
  • Tavistock Life Sciences
  • Tavros Therapeutics
  • Tetralogic Pharmaceuticals
  • The Chinese University of Hong Kong
  • The Column Group
  • The Institute of Cancer Research
  • The Kraft Group
  • The Michael J. Fox Foundation
  • The Netherlands Cancer Institute
  • The Silverstein Foundation for Parkinson’s with GBA
  • Third Rock Ventures
  • Tigermed
  • Tokalas
  • Trilo Therapeutics
  • Trinitas Capital
  • Tybourne Capital Management
  • UbiQ Bio
  • Ubiquigent
  • Ubix Therapeutics
  • UCLA Jonsson Comprehensive Cancer Center
  • Unionen
  • University Health Network
  • University Hospital Erlangen
  • University Hospital of Würzburg
  • University of California, Berkeley
  • University of California, San Francisco
  • University of Dundee
  • University of Florida
  • University of Illinois
  • University of Liverpool
  • University of Maryland, Baltimore
  • University of Michigan
  • University of Oxford
  • University of Southern Denmark
  • University of Tennessee Research Foundation
  • University of Washington
  • Vagelos College of Physicians and Surgeons
  • Versant Ventures
  • Vertex Pharmaceuticals
  • Vicore Pharma
  • Vida Ventures
  • Viking Global Investors
  • Vividion Therapeutics
  • VU University Medical Center
  • Washington University School of Medicine
  • Weill Medical College of Cornell University
  • Wellington Management
  • Woodford Patient Capital Trust
  • Wrocław Research Centre EIT+ 
  • X-Chem
  • Xios Therapeutics
  • Yale University
  • Yissum
  • Yuanhe Holdings
  • Yuansheng Venture Capital
  • Zenopharm
  • Zentalis Pharmaceuticals
  • Zentera
  • Zhuhai Huajin Capital
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...

Adroll
adroll